Rusfertide for polycythemia vera in Japanese adults
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new medicine called rusfertide for polycythemia vera (PV)—a blood condition where your body makes too many red blood cells. The trial aims to see if rusfertide can help reduce the need for blood removal procedures (phlebotomy) that PV patients currently need to manage their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and Japanese
- You have been diagnosed with polycythemia vera using current WHO guidelines
- You've needed frequent blood removal procedures (phlebotomies) recently—at least 3 in the past 7 months or at least 5 in the past year
- Your blood counts fall within acceptable ranges at screening (hematocrit under 45%, white blood cells 4,000–20,000, platelets 100,000–1,000,000)
- You are generally healthy enough for the trial (ECOG score 0, 1, or 2)
- If you're able to have children, you agree to use contraception during and for 30–90 days after the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called rusfertide for adults with polycythemia vera whose red blood cell levels are not well controlled. The drug is given as an injection and may help reduce the need for phlebotomy (blood removal) and manage symptoms.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
This study tests a new medicine called AG-236 in people with polycythemia vera (PV), a condition where the body makes too many red blood cells. The trial aims to see if AG-236 can reduce the need for phlebotomies (removing blood to lower red blood cell count) and help control the disease.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.